Clinical Trials
12 trialsNCT04864067 2026-05-08
NOAHS-ARC
Servicio de Salud Metropolitano Sur Oriente
Phase 2 Completed
NCT04309578 2026-04-03
A Study of Trastuzumab in Combination With Capecitabine and Cisplatin in Patients With Tissue HER2- But Serum HER2+ AGC
Asan Medical Center
Phase 2 Completed
NCT02795988 2025-04-16
A Study of IMU-131(HER-Vaxx) and Chemotherapy Compared to Chemotherapy Only in Patients With HER2 Positive Advanced Gastric Cancer
Imugene Limited
Phase 1/2 Completed
NCT03535727 2024-12-31
A Study of Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Metastatic Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2 Completed
NCT01404156 2024-08-28
POWERRANGER
CancerCare Manitoba
Phase 2/3 Completed
NCT01726582 2023-08-14
Pancreas Cancer: Molecular Profiling as a Guide to Therapy Before and After Surgery ("Personalized Medicine")
Medical College of Wisconsin
Phase 2 Completed
NCT01295086 2020-11-02
Taxotere®, Eloxatin® and Xeloda® (TEX) in Combination With Herceptin® as Treatment for HER2 Positive Non-resectable Cancer
Odense University Hospital
Phase NA Completed
NCT00215644 2018-11-02
MATRIX EG
Merck KGaA, Darmstadt, Germany
Phase 2 Completed
NCT00847119 2017-08-29
xeberecto
Institut Català d'Oncologia
Phase 2 Completed
NCT00548548 2017-06-14
AVAGAST
Genentech, Inc.
Phase 3 Completed
NCT00447330 2015-02-13
XAGastric
Duke University
Phase 2 Completed
NCT01161186 2012-10-11
Nab-paclitaxel (Abraxane), Gemcitabine, and Capecitabine (Xeloda) for Pancreatic Adenocarcinoma
University of California, San Francisco
Phase 1 Completed